Table 1. Baseline characteristics of study participants in Ziguinchor and Bignona, Senegal, 2016–2017.
| All subjects n (%) |
RUTF n (%) |
Food basket n (%) | p-value | |
|---|---|---|---|---|
| Number of participants, N | 26 | 12 | 14 | |
| Site | 1.00 | |||
| Ziguinchor | 13 (50.0) | 6 (50.0) | 7 (50.0) | |
| Bignona | 13 (50.0) | 6 (50.0) | 7 (50.0) | |
| Age, median years (IQR) | 46 (29–55) | 49 (34–55) | 40 (26–53) | 0.50 |
| Female | 13 (50.0) | 6 (50.0) | 7 (50.0) | 1.00 |
| Education | 0.96 | |||
| None | 8 (33.3) | 3 (30.0) | 5 (35.7) | |
| Primary school | 9 (37.5) | 4 (40.0) | 5 (35.7) | |
| Secondary school | 7 (29.2) | 3 (30.0) | 4 (28.6) | |
| Unemployed | 22 (84.6) | 10 (83.3) | 12 (85.7) | 1.00 |
| Household (HH) size, median (IQR) | 11 (7–16) | 10 (7–17) | 13 (7–16) | 0.57 |
| HH members age <5, median (IQR) | 2 (0–3) | 2 (1–2) | 2 (0–3) | 0.89 |
| HH members age ≥18, median (IQR) | 8 (5–11) | 7 (5–10) | 8 (5–12) | 0.55 |
| All household members unemployed | 15 (57.7) | 8 (66.7) | 7 (50.0) | 0.39 |
| Clinic transportation time, round trip (minutes), median (IQR) | 60 (30–120) | 75 (30–120) | 60 (28–120) | 0.46 |
| Clinic transportation expenditure, round trip median (IQR) | $1.66 ($0.66 -$1.99) |
$1.66 ($0.33-$1.99) |
$1.66 ($0.66-$2.24) |
0.77 |
| Daily household food expenditure, median (IQR) | $1.66 ($0.83 -$4.15) |
$1.66 ($0.83 -$4.15) |
$2.49 ($0.83 -$4.36) |
0.74 |
| HIV type | 0.67 | |||
| HIV-1 | 19 (73.1) | 8 (66.7) | 11 (78.6) | |
| HIV-2 | 7 (26.9) | 4 (33.3) | 3 (21.4) | |
| History of WHO stage 3 or 4 conditions | ||||
| Fever >1m | 9 (34.6) | 4 (33.3) | 5 (35.7) | 1.00 |
| Weight loss >10% | 26 (100) | 12 (100) | 14 (100) | - |
| Diarrhea >1m | 7 (26.9) | 1 (8.3) | 6 (42.9) | 0.08 |
| Pulmonary TB | 26 (100) | 12 (100) | 14 (100) | - |
| Co-trimoxazole | 17 (89.5) | 9 (90.0) | 8 (88.9) | 1.00 |
| On ART before enrollment | 14 (56.0) | 5 (45.5) | 9 (64.3) | 0.44 |
| ART regimen | 0.59 | |||
| TDF + 3TC + EFV | 17 (65.4) | 7 (58.3) | 10 (71.4) | |
| Triple NRTI | 5 (19.2) | 3 (25.0) | 2 (14.3) | |
| LPV/r-based regimen* | 3 (11.5) | 1 (8.3) | 2 (14.3) | |
| TDF + 3TC + NVP* | 1 (3.8) | 1 (8.3) | 0 (0) | |
| TB diagnosis | 0.72 | |||
| Both sputum smear and Xpert positive | 7 (26.9) | 4 (33.3) | 3 (21.4) | |
| Positive sputum smear only | 12 (46.2) | 6 (50.0) | 6 (42.9) | |
| Positive Xpert only | 4 (15.4) | 1 (8.3) | 3 (21.4) | |
| Clinical | 3 (11.5) | 1 (8.3) | 2 (14.3) | |
| Directly Observed Therapy (DOT) | 0.14 | |||
| No DOT | 15 (57.7) | 6 (66.7) | 9 (64.3) | |
| DOT by health-care worker | 2 (7.7) | 0 (0) | 2 (14.3) | |
| DOT by family member | 6 (23.1) | 3 (33.3) | 3 (21.4) | |
| Not documented | 3 (11.5) | 3 (25.0) | 0 (0) | |
| TB treatment regimen: 2HRZE/4HR | 24 (92.3) | 11 (91.7) | 13 (92.9) | 0.54 |
| Days between TB diagnosis and TB treatment initiation, median (IQR) | 0 (0–1.25) | 0 (0–1.50) | 0 (0–1.50) | 0.95 |
*The co-administration of rifampin with nevirapine or protease-inhibitors is not recommended.